Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term

Randomized adjuvant trials continue to show significant reductions in distant recurrence and death for early-stage women treated with adjuvant trastuzumab. BCIRG-006 showed superior disease-free and overall survival of two trastuzumab-containing regimens in comparison to a non-trastuzumab-containing...

Descripción completa

Detalles Bibliográficos
Autores principales: Jankowitz, Rachel C, Brufsky, Adam M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446365/
https://www.ncbi.nlm.nih.gov/pubmed/22546039
http://dx.doi.org/10.1186/bcr3120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446365/
https://www.ncbi.nlm.nih.gov/pubmed/22546039
http://dx.doi.org/10.1186/bcr3120

Ejemplares similares